Amer et al. performed a systematic review and meta-analysis of the impact of a higher level of Il-6 (23.88 pg/mL) in late stages of ovarian cancer compared to earlier ones (16.67 pg/mL). This evidence concerns the gene IL6 and ovarian cancer.